CAMBRIDGE, Mass., July 29, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced participation in two investor conferences in August: BTIG virtual Biotechnology Conference, August 5-6, 2024, and Canaccord Genuity (CG) 44th Annual Growth Conference, August 13-14, 2024 in Boston.BTIG Biotechnology ConferenceJohn Butler, Chief Executive Officer, will participate in a fireside chat on ...

Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and improve economicsAnnounced Vafseo WAC pricing of $1,278 for a 30-day supplySubmitted TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025Akebia to host investor conference call at 8:00 a.m. ET on July 11, 2024CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (N ...

CAMBRIDGE, Mass., June 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024. Mr. Butler will present at 9:30 a.m. ET to provide updates on the progress of commercial launch activities for Vafseo® (vadadustat) Tablets.A webcast of the ...

财务数据和关键指标变化 - 总收入为32.6百万美元,较上年同期下降18.5% [40] - 产品净收入为31百万美元,较上年同期下降10.7% [40] - 毛利润为21百万美元,较上年同期下降35.6% [43][44] - 研发费用为9.7百万美元,较上年同期下降50.8% [45] - 销售及管理费用为25.4百万美元,较上年同期增长1.2% [46] - 净亏损为18百万美元,较上年同期减少33.1% [46] - 现金及现金等价物为42百万美元,另外还有8百万美元的债务融资 [37][38] 各条业务线数据和关键指标变化 - Auryxia产品收入下降,主要是由于合同策略调整 [40] - 公司计划在2025年将磷酸盐结合剂纳入透析套餐,这将有利于Auryxia的销售 [41][42] 各个市场数据和关键指标变化 - 欧洲市场方面,公司的合作伙伴MEDICE计划于6月1日在德国和奥地利推出Vafseo,并计划在2024年底前在荷兰、瑞士、瑞典、挪威和芬兰推出 [31] 公司战略和发展方向及行业竞争 - 公司正在推进Vafseo在透析患者中的广泛应用,并计划探讨将其用于非透析慢性肾病患者 [13][14][35] - 公司正在与FDA就非透析患者适应症展开讨论,并计划进行新的临床试验 [14] - 公司正在与主要透析机构进行合同谈判,以确定Vafseo的WACC价格 [28][29] - 公司计划在2025年1月完成TDAPA申请,届时Vafseo将获得广泛报销和使用 [30] - 公司正在与关键研究者和透析机构合作,开展临床研究以支持Vafseo的进一步应用 [33][34] 管理层对经营环境和未来前景的评论 - 管理层对Vafseo在透析市场的反响和采用情况感到鼓舞 [9][10] - 管理层认为Vafseo的标签支持其在透析患者中的广泛应用,并有望成为新的口服标准治疗 [11][12] - 管理层表示将继续努力探索Vafseo在非透析慢性肾病患者中的适用性,这是公司的重要价值驱动因素 [35] 其他重要信息 - 公司正在积极推进Auryxia在欧洲的上市申请,如获批将由合作伙伴Averoa负责上市和销售 [43] - 公司已经简化了与Vifor的工作资本协议,将以特许权使用费的形式偿还相关款项 [39] 问答环节重要的提问和回答 问题1 **Ali Bratzel 提问** 请详细说明Vifor许可协议的修订及其对公司的影响 [48][49][50] **John Butler 回答** 公司之前与Vifor签订了一项工作资本协议,Vifor提供4000万美元用于Vafseo的采购。现在公司已将该协议修订为特许权使用费的形式,在未来几年内分期偿还。这种方式更加简单明了,对公司现金流的影响与之前的安排基本一致 [49][50] 问题2 **Ali Bratzel 提问** 您提到现金和资源可支持至少2年的运营,请说明相关假设 [51] **John Butler 回答** 公司目前的现金储备加上Auryxia和Vafseo的销售收入,预计可支持至少2年的运营。对于Auryxia,公司保持谨慎态度,考虑到专利到期的影响。而对于Vafseo的销售,公司也采取了相对保守的预测 [52][53]

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.05 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Akebia Th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share AKBA The Nasdaq Capital Market Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION ...

Exhibit 99.1 Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Akebia to host conference call at 8:00 a.m. ET on May 9 • Vafseo® (vadadustat) tablets FDA approved on March 27, 2024 • Vafseo launch activities underway with availability expected in January 2025 • Auryxia® (ferric citrate) net product revenues were $31.0 million for the first quarter 2024, Akebia expects 2024 Auryxia net product revenue growth versus 2023 CAMBRIDGE, Mass.—May 9, 2024—Akebia Therape ...

Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 9, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call by phone, please click on this Regi ...

Key PointsAkebia Therapeutics is a biotech specializing in treatments for chronic kidney diseases (CKD).Its lead drug, Vafseo, received FDA approval for treating anemia in adult CKD patients who have at least 3 months of dialysis.Vafseo is an oral tablet that has been approved in 37 countries.5 stocks we like better than Akebia TherapeuticsAkebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for pat ...

公司概况 - Akebia Therapeutics, Inc.（Nasdaq: AKBA）是一家生物制药公司，旨在改善肾脏疾病患者的生活[1] - Akebia Therapeutics成立于2007年，总部位于马萨诸塞州剑桥市[3] 员工期权 - 公司于2024年3月28日向六名新员工授予了购买总计110,000股Akebia普通股的期权，作为这些员工进入公司就业的诱因[1] - 这些期权的行权价格为每股1.83美元，与授予日Akebia普通股的收盘价相等[2] - 期权将在四年内解锁，首年解锁25％的股份，其余75％的股份每季度解锁，前提是新员工继续在Akebia工作[2] - 每个期权有10年期限，受Akebia诱因奖励计划和股票期权协议的条款和条件约束[2]